{"title":"Current Antifungals and the Developing Pipeline.","authors":"Melissa D Johnson, W Justin Moore","doi":"10.1016/j.idc.2025.01.001","DOIUrl":null,"url":null,"abstract":"<p><p>Prevention and management of invasive fungal infections is challenging due to the complexity of at-risk patient population, high morbidity and mortality of these infections, and pharmacologic aspects of available antifungal agents. While there has been substantial investment in antifungal drug development over past 20 years, the ideal antifungal remains elusive. Clinicians must be aware of differences in spectrum of activity, pharmacokinetic/dynamic dosing, toxicity, resistance, and drug interaction profiles of antifungals to use them most effectively. This article will review key features of U.S. Food and Drug Administration-approved and pipeline antifungals to facilitate an understanding of their role in treatment and/or prevention of invasive fungal infections.</p>","PeriodicalId":13562,"journal":{"name":"Infectious disease clinics of North America","volume":" ","pages":""},"PeriodicalIF":6.1000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious disease clinics of North America","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.idc.2025.01.001","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Prevention and management of invasive fungal infections is challenging due to the complexity of at-risk patient population, high morbidity and mortality of these infections, and pharmacologic aspects of available antifungal agents. While there has been substantial investment in antifungal drug development over past 20 years, the ideal antifungal remains elusive. Clinicians must be aware of differences in spectrum of activity, pharmacokinetic/dynamic dosing, toxicity, resistance, and drug interaction profiles of antifungals to use them most effectively. This article will review key features of U.S. Food and Drug Administration-approved and pipeline antifungals to facilitate an understanding of their role in treatment and/or prevention of invasive fungal infections.
期刊介绍：
Infectious Disease Clinics of North America updates you on the latest trends in the clinical diagnosis and management of patients with infectious diseases, keeps you up to date on the newest advances, and provides a sound basis for choosing treatment options. Each issue focuses on a single topic in infectious disease, including clinical microbiology, compromised host infections, gastrointestinal infections, global health, hepatitis, HIV/AIDS, hospital-acquired infections, travel medicine, infection control, bacterial infections, sexually transmitted diseases, urinary tract infections, and viral infections.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
